According to researcher, the treatment offers improved retinal sensitivity, visual function, and mobility.
Ophthalmology Times: December 2022
Ophthalmologist discusses the impact of getting older on patients diagnosed with the disease.
CXL has been proven effective to treat patients with corneal ectasias.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy
4
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
5
.png "Optometry Times"){kind=logo}
